Author: "M. Velten" / Topic: business - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"M. Velten"' showing total 43 results

Start Over Author "M. Velten" Topic business

43 results on '"M. Velten"'

1. Cost-effectiveness analysis of resorbable biosynthetic mesh in contaminated ventral hernia repair

Author: Cécile Brigand, M. Velten, C. Boisson, Benoit Romain, D. Charleux-Muller, and Catherine Lejeune
Subjects: medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Context (language use), 030230 surgery, 03 medical and health sciences, 0302 clinical medicine, Ambulatory care, Recurrence, medicine, Humans, Herniorrhaphy, Retrospective Studies, Biological Products, Ventral hernia repair, business.industry, General Medicine, Cost-effectiveness analysis, Surgical Mesh, University hospital, Hernia, Ventral, Surgery, Treatment Outcome, 030220 oncology & carcinogenesis, Complication, business, Decision analysis
Abstract: Summary Background The aim of this study was to compare, in terms of cost and serious complications, the use of biosynthetic resorbable parietal mesh with biologic mesh in patients undergoing contaminated ventral hernia repair (modified Ventral Hernia Working Group grade 3). Poly-4-hydroxy-butyrate (P4HB) biosynthetic mesh has rarely been the subject of comparative studies in the context of contamination. Data are required to confirm the effects of a transition from biological mesh to biosynthetic resorbable mesh. Patients and methods A cost-effectiveness analysis was conducted. It was based on a decision analysis model built with clinical and economic data issued from a before-after study that included 94 patients hospitalized for ventral hernia repair at the University Hospital of Strasbourg (France) from June 2011 to February 2018. The effectiveness endpoint was the number of patients presenting with a serious specific complication or a general complication at 6 months. Data for surgical hospitalization stays, home hospitalizations and ambulatory care costs were included. Results We found fewer serious complications with biosynthetic mesh: 21% versus 33% with biologic mesh. A cost savings of US $5146 was determined. Deterministic sensitivity analyses and a probabilistic analysis confirmed our findings and the robustness of the model. Conclusion P4HB biosynthetic resorbable mesh appeared to be the most effective and the least costly option. Additional data will be needed to confirm the superiority of biosynthetic mesh in terms of the recurrence risk reduction over a longer period.
Published: 2022
Full Text: View/download PDF

2. 994 Impact of lymphadenectomy on survival of patients with serous advanced ovarian cancer after neoadjuvant chemotherapy: a national multicenter study

Author: Charles Coutant, M. Koskas, J.-J. Baldauf, Marcos Ballester, M Demarchi, L. Ouldamer, G Canlorbe, Pierre Collinet, J Gantzer, T Touboul, Emilie Faller, V Bund, C. Huchon, V Lavoue, Pierre Adrien Bolze, L Lecointre, Thomas Boisramé, M Velten, C Akladios, and Sofiane Bendifallah
Subjects: Oncology, medicine.medical_specialty, education.field_of_study, Chemotherapy, Proportional hazards model, business.industry, medicine.medical_treatment, Population, Debulking, Serous fluid, Internal medicine, Ovarian carcinoma, medicine, Lymphadenectomy, education, business, Cohort study
Abstract: Title: Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN). Introduction/Background* The population of interest to this study comprised individuals with advanced-stage ovarian carcinoma who were exposed to neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). Those who had not received systematic lymphadenectomy (SL; Group 1) were compared to those who had received SL (Group 2). Outcome measures included progression-free survival (PFS), overall survival (OS), and surgical complications. (Group 1). Methodology This was a retrospective, multicenter cohort study in nine referral centers of France between January 2000 and June 2017. OS analysis using the multivariate Cox regression model was performed. PFS and surgery-related morbidity were analyzed. Result(s)* Of the 255 patients included, 100 were in Group 1 and 155 in Group 2. Patient majority was, on average, younger and less comorbid, with predominant R0 surgery in Group 2. Dindo–Clavien score was similar between the two groups (p = 0.15). Median OS was 26.8 months in Group 2 and 27.6 months in Group 1. SL was not statistically significant on OS (p = 0.7). Median PFS was 18.3 months in Group 2 and 16.6 months in Group 1. SL had positive impact on PFS (p = 0.005). Conclusion* Patients who had received SL (Group 2) had significantly higher PFS regardless of node-positivity status when compared to those who had not received SL
Published: 2021
Full Text: View/download PDF

3. Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author: Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis, Tıp Fakültesi, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis
Subjects: 0301 basic medicine, Universal Health Coverage, population-based registries, Relative Survival, Settore MED/42 - Igiene Generale E Applicata, Cancer -- Treatment, Humans, Neoplasms, Population Surveillance, Registries, Survival Rate, Medicine (all), 0302 clinical medicine, cancer survival, education.field_of_study, Relative survival, EPICENE, General Medicine, 3. Good health, trend, 030220 oncology & carcinogenesis, Public-Health, cancer surveillance, Liver cancer, survival, cancer registry, CONCORD-3, Cure, Childhood-Cancer, medicine.medical_specialty, population-based cancer registries, Womens Cancers, Population, Medicine (all),cancer survival, population-based cancer registries, Socio-culturale, United-States, Article, 03 medical and health sciences, Breast cancer, Cancer epidemiology, medicine, Nordic-Countries, Cancer -- Mortality, education, Survival rate, Cancer prevention, Alternative Approach, business.industry, Public health, Cancer, Cancer -- Patients -- Long-term care, medicine.disease, 030104 developmental biology, High-Income Countries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract: Eser, Sultan (Balikesir Author), Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., American Cancer Society Centers for Disease Control and Prevention Swiss Re Swiss Cancer Research foundation Swiss Cancer League Institut National du Cancer La Ligue Contre le Cancer Rossy Family Foundation US National Cancer Institute Susan G Komen Foundation
Published: 2018
Full Text: View/download PDF

4. 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

Author: M. Garcia-Ramirez, A. Pechery, M. Velten, Alexandre Coutte, N. Etienne-Selloum, X. Sun, Sylvie Zanetta, Thierry Chatellier, Marc Alfonsi, Christian Borel, Y. Hammoud, G. Bera, M. Wanneveich, Jean Bourhis, M.-H. Girard-Calais, E. Gherga, J.-P. Pignon, and G. Janoray
Subjects: Cisplatin, Oncology, medicine.medical_specialty, Squamous cell cancer, business.industry, medicine.medical_treatment, Locally advanced, Head neck, Hematology, law.invention, Radiation therapy, Randomized controlled trial, law, Concomitant, Internal medicine, Medicine, business, medicine.drug
Published: 2020
Full Text: View/download PDF

5. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

Author: Roberta De Angelis, Pamela Minicozzi, Milena Sant, Luigino Dal Maso, David H. Brewster, Gemma Osca-Gelis, Otto Visser, Marc Maynadié, Rafael Marcos-Gragera, Xavier Troussard, Dominic Agius, Paolo Roazzi, Elisabetta Meneghini, Alain Monnereau, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Cancer registry, Europe, Hodgkin lymphoma, Leukaemia, Lymphoma, Multiple myeloma, Non-Hodgkin lymphoma, Relative survival, Cancer Research, education.field_of_study, medicine.medical_specialty, Myeloid, business.industry, Population, Follicular lymphoma, Plasma cell neoplasm, medicine.disease, medicine.anatomical_structure, hemic and lymphatic diseases, Internal medicine, Immunology, Medicine, education, business, International Classification of Diseases for Oncology
Abstract: BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participating cancer registries from 29 European countries. Mean survival in Europe was calculated as the population weighted average of country-specific estimates. RESULTS: On average in Europe, 5-year relative survival was highest for Hodgkin lymphoma (81% ; 40, 625 cases), poorest for acute myeloid leukaemia (17% ; 57, 026 cases), and intermediate for non- Hodgkin lymphoma (59% ; 329, 204 cases), chronic myeloid leukaemia (53% ; 17, 713 cases) and plasma cell neoplasms (39% ; 94, 024 cases). Survival was generally lower in Eastern Europe and highest in Central and Northern Europe. Wider between country differences (>10%) were observed for malignancies that benefited from therapeutic advances, such as chronic myeloid leukaemia, chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma and multiple myeloma. Lower differences (
Published: 2015
Full Text: View/download PDF

6. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study

Author: Otto Visser, Eva Ardanaz, Laura Botta, Milena Sant, Andrea Tavilla, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Ependymoma, Cancer Research, medicine.medical_specialty, Pediatrics, Oligoastrocytoma, Relative survival, business.industry, Cancer, Astrocytoma, medicine.disease, Cancer registry, Internal medicine, medicine, Brain tumours, Survival, Oligodendroglioma, business, Pathological
Abstract: Background Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000–2007 in Europe. Methods For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999–2001, 2002–2004 and 2005–2007). Results Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10–12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74 years of age. Conclusions Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.
Published: 2015
Full Text: View/download PDF

7. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Author: Bernd Holleczek, Silvia Rossi, Agius Domenic, Kaire Innos, Pamela Minicozzi, Silvia Francisci, Monika Hackl, Nora Eisemann, Hermann Brenner, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Cancer Research, medicine.medical_specialty, education.field_of_study, Relative survival, Colorectal cancer, business.industry, Cancer registries, EUROCARE-5 study, Population-based, Population, Age at diagnosis, Cancer, Rectum, Treatment options, medicine.disease, digestive system diseases, Surgery, medicine.anatomical_structure, Oncology, Internal medicine, Cohort, medicine, business, education
Abstract: Background Previous population-based studies revealed major variation in survival for patients with colorectal cancer (CRC) in Europe by age and between different countries and regions, but also a sustained improvement in survival for patients with CRC in recent years. This EUROCARE-5 paper aims to update available knowledge from previous studies and to provide the latest survival estimates for CRC patients from Europe. Methods The study analysed data of patients diagnosed with CRC from population-based cancer registries diagnosed in 29 European countries. Estimates of 1-year and 5-year relative survival (RS) were derived for patients diagnosed in 2000–2007 by European region, country and age at diagnosis. Additionally to these cohort estimates, time trends in 5-year RS were obtained for the calendar periods 1999–2001 and 2005–2007, using the period analysis methodology. Results European average 5-year RS for patients diagnosed with colon and rectum cancer was 57% and 56%, respectively. The analyses showed persistent differences in cancer survival across Europe with lowest survival for CRC patients observed in Eastern Europe. The analyses further showed a strong gradient in age-specific survival. Even though the study revealed sustained improvement in patient survival between 1999–2001 and 2005–2007 (absolute increase of 4 and 6 percentage points for colon and rectum, respectively), the differences in the survival for CRC patients observed at the beginning of the millennium persisted over time. Conclusion Although survival for CRC patients in Europe improved markedly in the study period, significant geographic variations and a strong age gradient still persisted. Enhanced access to effective diagnostic procedures and treatment options might be the keys to reducing the existing disparities in the survival of CRC patients across Europe.
Published: 2015
Full Text: View/download PDF

8. Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study

Author: Milena Sant, Maria Dolores Chirlaque Lopez, Roberto Agresti, Maria José Sánchez Pérez, Bernd Holleczek, Magdalena Bielska-Lasota, Nadya Dimitrova, Kaire Innos, Alexander Katalinic, Hilde Langseth, Nerea Larrañaga, Silvia Rossi, Sabine Siesling, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
Subjects: Gynecology, Cervical cancer, Cancer Research, medicine.medical_specialty, education.field_of_study, Vaginal cancer, Relative survival, business.industry, Obstetrics, Population, Cancer, Breast cancer, Corpus uteri cancer, Europe, Ovarian cancer, Population-based, Survival, Vulval cancer, Vulvar cancer, medicine.disease, medicine.anatomical_structure, Oncology, medicine, METIS-311843, IR-97294, business, education, Cervix
Abstract: BACKGROUND: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. METHODS: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions. We used the cohort approach to estimate 5-year relative survival (RS) for adult (⩾15years) women diagnosed 2000-2007, by age, country and region ; and the period approach to estimate time trends (1999-2007) in RS for breast and cervical cancers. RESULTS: In 2000-2007, 5-year RS was 57% overall, 82% for women diagnosed with breast, 76% with corpus uteri, 62% with cervical, 38% with ovarian, 40% with vaginal and 62% with vulvar cancer. Survival was low for patients resident in Eastern Europe (34% ovary-74% breast) and Ireland and the United Kingdom [Ireland/UK] (31-79%) and high for those resident in Northern Europe (41-85%) except Denmark. Survival decreased with advancing age: markedly for women with ovarian (71% 15-44years ; 20% ⩾75years) and breast (86% ; 72%) cancers. Survival for patients with breast and cervical cancers increased from 1999-2001 to 2005-2007, remarkably for those resident in countries with initially low survival. CONCLUSIONS: Despite increases over time, survival for women's cancers remained poor in Eastern Europe, likely due to advanced stage at diagnosis and/or suboptimum access to adequate care. Low survival for women living in Ireland/UK and Denmark could indicate late detection, possibly related also to referral delay. Poor survival for ovarian cancer across the continent and over time suggests the need for a major research effort to improve prognosis for this common cancer.
Published: 2015
Full Text: View/download PDF

9. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Author: L. Dal Maso, A. Tavilla, F. Pacini, D. Serraino, B.A.C. van Dijk, M.D. Chirlaque, R. Capocaccia, N. Larrañaga, M. Colonna, D. Agius, E. Ardanaz, J. Rubió-Casadevall, A. Kowalska, S. Virdone, S. Mallone, H. Amash, R. De Angelis, M. Hackl, N. Zielonke, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, L. Dušek, M. Zvolský, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, A.V. Guizard, J. Faivre, A.S. Woronoff, B. Tretarre, N. Bossard, Z. Uhry, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, A. Barchielli, A. Caldarella, G. Gatta, M. Sant, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, A. Zucchetto, M. Caldora, E. Carrani, S. Francisci, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, F. Pannozzo, S. Busco, R.A. Filiberti, M. Vercelli, P. Ricci, M. Autelitano, G. Spagnoli, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, L. Mangone, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, M. Rugge, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, T.B. Johannesen, J. Rachtan, S. Góźdź, R. Mężyk, J. Błaszczyk, M. Bębenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, C. Safaei Diba, M. Primic-Zakelj, M. Errezola, J. Bidaurrazaga, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, E. Molina, C. Navarro, C. Moreno-Iribas, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Ho, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Rashbass, J. Broggio, J. Verne, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, Registre des cancers du Tarn, France, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Registre général des cancers du Tarn, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Dal Maso L., Tavilla A., Pacini F., Serraino D., van Dijk B.A.C., Chirlaque M.D., Capocaccia R., Larranaga N., Colonna M., Agius D., Ardanaz E., Rubio-Casadevall J., Kowalska A., Virdone S., Mallone S., Amash H., De Angelis R., Hackl M., Zielonke N., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Dusek L., Zvolsky M., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Guizard A.V., Faivre J., Woronoff A.S., Tretarre B., Bossard N., Uhry Z., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sutera Sardo A., Ferretti S., Mazzei A., Caldarella A., Gatta G., Sant M., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Zucchetto A., Caldora M., Carrani E., Francisci S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Pannozzo F., Busco S., Filiberti R.A., Vercelli M., Ricci P., Autelitano M., Spagnoli G., Cirilli C., Fusco M., Vitale M.F., Usala M., Vitale F., Ravazzolo B., Michiara M., Tumino R., Mangone L., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Rugge M., Tognazzo S., Pildava S., Smailyte G., Calleja N., Johannesen T.B., Rachtan J., Gozdz S., Mezyk R., Blaszczyk J., Bebenek M., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Safaei Diba C., Primic-Zakelj M., Errezola M., Bidaurrazaga J., Diaz Garcia J.M., Marcos-Navarro A.I., Marcos-Gragera R., Izquierdo Font A., Sanchez M.J., Molina E., Navarro C., Moreno-Iribas C., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Ho V., Otter R., Coleman M., Allemani C., Rachet B., Rashbass J., Broggio J., Verne J., Gavin A., Donnelly C., Brewster D.H., Huws D.W., and White C.
Subjects: Registrie, Male, Cancer Research, IMPACT, Cancer registrie, [SDV]Life Sciences [q-bio], Papillary, 0302 clinical medicine, QUALITY-OF-LIFE, Residence Characteristics, Adenocarcinoma, Follicular, Cancer registries, Registries, Thyroid cancer, Thyroid Neoplasm, education.field_of_study, Relative survival, Incidence (epidemiology), Mortality rate, Incidence, Diagnosis-Related Group, EUROCARE, Europe, Adolescent, Adult, Aged, Carcinoma, Carcinoma, Papillary, Diagnosis-Related Groups, Female, Humans, Middle Aged, Sex Distribution, Thyroid Neoplasms, Young Adult, Oncology, PREVALENCE, 3. Good health, Thyroid Cancer, Papillary, 030220 oncology & carcinogenesis, Cohort, Human, medicine.medical_specialty, Population, GEOGRAPHICAL-DISTRIBUTION, UNITED-STATES, Socio-culturale, 030209 endocrinology & metabolism, Adenocarcinoma, RECENT TRENDS, 03 medical and health sciences, MANAGEMENT, medicine, education, Survival rate, business.industry, MORTALITY, Follicular, medicine.disease, Cancer registry, Surgery, MICROCARCINOMA, Residence Characteristic, business, Demography
Abstract: Background: Incidence rates of thyroid cancer (TC) increased in several countries during the last 30 years, while mortality rates remained unchanged, raising important questions for treatment and follow-up of TC patients. This study updates population-based estimates of relative survival (RS) after TC diagnosis in Europe by sex, country, age, period and histology.Methods: Data from 87 cancer registries in 29 countries were extracted from the EUROCARE-5 dataset. One-and 5-year RS were estimated using the cohort approach for 86,690 adult TC patients diagnosed in 2000-2007 and followed-up to 12/31/2008. RS trends in 1999-2007 and 10-year RS in 2005-2007 were estimated using the period approach.Results: In Europe 2000-2007, 5-year RS after TC was 88% in women and 81% in men. Survival rates varied by country and were strongly correlated (Pearson rho = 75%) with country-specific incidence rates. Five-year RS decreased with age (in women from > 95% at age 15-54 to 57% at age 75+), from 98% in women and 94% in men with papillary TC to 14% in women and 12% in men with anaplastic TC. Proportion of papillary TC varied by country and increased over time, while survival rates were similar across areas and periods. In 1999-2007, 5-year RS increased by five percentage points for all TCs but only by two for papillary and by four for follicular TC. Ten-year RS in 2005-2007 was 89% in women and 79% in men.Conclusions: The reported increasing TC survival trend and differences by area are mainly explained by the varying histological case-mix of cases. (C) 2017 Elsevier Ltd. All rights reserved.
Published: 2017
Full Text: View/download PDF

10. Role of Thyroid Surgery in the Obstructive Sleep Apnea Syndrome

Author: M. Velten, K. Bourahla, Jean-François Rodier, A. Schneider, C. Petiau, and P. P. Volkmar
Subjects: Male, medicine.medical_specialty, medicine.medical_treatment, Comorbidity, Polysomnography, Body Mass Index, Humans, Medicine, Postoperative Period, Prospective Studies, Continuous positive airway pressure, Aged, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure, medicine.diagnostic_test, Goiter, business.industry, Thyroidectomy, Apnea, Sleep apnea, Middle Aged, medicine.disease, nervous system diseases, respiratory tract diseases, Surgery, Obstructive sleep apnea, Treatment Outcome, Anesthesia, Female, medicine.symptom, business, Hypopnea, Abdominal surgery
Abstract: To study the impact of thyroid surgery on obstructive sleep apnea syndrome (OSAS) evaluated by the apnea/hypopnea index (AHI) was studied. Secondary objectives were to evaluate the impact on the positional component of OSAS and to highlight possible predictors of improvement of OSAS after thyroidectomy. Twenty-eight patients with OSAS are included in this monocentric study: they underwent total thyroidectomy (n = 26) or left loboisthmectomy. Postoperative assessment involves a nocturnal control polysomnography as of 60 days after surgery. The mean age at the time of surgery is 61.3 years (standard deviation ±7.3) and average body mass index is 29.6 kg/m2 (±7.3). Continuous positive airway pressure (CPAP) treatment is introduced preoperatively in 82 % of patients. The statistical analysis shows a significant decrease of 33 % in postoperative AHI for the total population (p = 0.001), 77 % in patients under CPAP (p = 0.05), and 27 % in patients without CPAP (p = 0.02). CPAP therapy could be released in four patients. Given the limited number of subjects studied, the surgery did not impact on the positional component of the OSAS. Statistical analysis failed to link a predictive factor to AHI reduction. We propose thyroid surgery as an alternative or as a complement to CPAP treatment for the patients with goitre: it allows a significant decrease in postoperative AHI, allowing adaptation of the CPAP treatment downward, or even a release in some cases. These results need to be confirmed on a larger series of patients in a prospective study with standardized criteria for polysomnography and multivariate analysis.
Published: 2014
Full Text: View/download PDF

11. Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva

Author: T. Petit, P. Volkmar, D. Weitbruch, P. Quetin, S. Heymann, F. Bodin, J.F. Rodier, A. Gaudineau, and M. Velten
Subjects: Vulvar neoplasm, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Articles, Surgery, Vulva, Radiation therapy, medicine.anatomical_structure, Oncology, Interquartile range, Concomitant, Radical Vulvectomy, medicine, Lymphadenectomy, business, Neoadjuvant therapy
Abstract: Alternative therapies have been sought to alleviate mutilation and morbidity associated with surgery for vulvar neoplasms. Our prime objective was to assess tumor absence in pathological vulvar and nodal specimens following neoadjuvant chemoradiotherapy in locally advanced vulvar neoplasms. Data were retrospectively collected from January 2001 to May 2009 from 22 patients treated with neoadjuvant therapy for locally advanced squamous cell carcinoma of the vulva. Neoadjuvant treatment consisted of inguino-pelvic radiotherapy (50 Gy) in association with chemotherapy when possible. Surgery occurred at intervals of between 5 to 8 weeks. The median age of patients at diagnosis was 74.1 years. All patients were primarily treated with radiotherapy and 15 received a concomitant chemotherapy. Additionally, all patients underwent radical vulvectomy and bilateral inguino-femoral lymphadenectomy. Tumor absence in the vulvar and nodal pathological specimens was achieved for 6 (27%) patients, while absence in the vulvar pathological specimens was only achieved for 10 (45.4%) patients. Postoperative follow-up revealed breakdown of groin wounds, vulvar wounds and chronic lymphedema in 3 (14.3%), 7 (31.8%) and 14 cases (63.6%), respectively. Within a median follow-up time of 2.3 years [interquartile range (IQR), 0.6-4.6], 12 (54.6%) patients experienced complete remission and 6 cases succumbed to metastatic evolution within a median of 2.2 years (IQR, 0.6-4.6), with 1 case also experiencing perineal recurrence. Median survival time, estimated using the Kaplan-Meier method, was 5.1 years (IQR, 1.0-6.8). We suggest that neoadjuvant chemoradiotherapy may represent a reliable and promising strategy in locally advanced squamous cell carcinoma of the vulva.
Published: 2012
Full Text: View/download PDF

12. Existe-t-il un lien entre un événement psychique et le risque de survenue d’un cancer ?

Author: H. Sancho-Garnier, M. Velten, and S. Schraub
Subjects: medicine.medical_specialty, Epidemiology, business.industry, media_common.quotation_subject, Public Health, Environmental and Occupational Health, Case-control study, Cancer, medicine.disease, Personality disorders, Breast cancer, medicine, Personality, Risk factor, business, Psychiatry, Cohort study, media_common
Abstract: Background The possibility that life events, personality, or depression can be considered cancer risk factors has been of great interest among the lay public and doctors. Methods A critical review of different publications of meta-analyses, case–control studies, and cohort studies investigating a possible relation between the onset of cancer and life events, personality disorders, or depression is presented. Many studies have methodological limitations with possible bias, which may explain controversial results. We selected 32 studies from which conclusions can be drawn with the least amount of bias. Results Eighteen out of 32 publications whose methodology permits unbiased interpretation show no link between psychological factors and the risk of cancer. Six publications show a significant link only in one or several subgroups and four surveys, three of which were published by the same author, show an inverse relation in gynecological cancers. As for life events and breast cancer, the results are slightly in favor of a positive relation in four studies; four others showed no relation, and one argues in favor of an inverse risk, which means a protective effect for this cancer. For life events and other cancers, studies show no relation, with the possible exception of cancers in women where endogenous estrogens can play a role (colon and endometrial cancers), where there is an inverse relation. No studies showed a significant relation between personality features and the risk of cancer. The studies of a possible relation between depression and cancer are controversial and no conclusion can be drawn. Conclusion It cannot be confidently concluded that life events, personality features, or depression play a role in the onset of cancer.
Published: 2009
Full Text: View/download PDF

13. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study

Author: Emanuele Crocetti, Sandra Mallone, Trude Eid Robsahm, Anna Gavin, Domenic Agius, Eva Ardanaz, Maria-Dolores Chirlaque Lopez, Kaire Innos, Pamela Minicozzi, Lorenzo Borgognoni, Daniela Pierannunzio, Nora Eisemann, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert- Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, A. Caldarella, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, null Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, null Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Pathology, medicine.medical_specialty, European populations, Cancer Research, Relative survival, business.industry, Time trends, Cancer survival, EUROCARE, Registries, Skin melanoma, Confidence interval, Eastern european, Oncology, SDG 3 - Good Health and Well-being, medicine, Overdiagnosis, business, Demography
Abstract: Background In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe.Methods Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15 years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered. Results In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83-84%). The highest values were found for patients resident in Northern (88%; 87-88%) and Central (88%; 87-88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85-86%) and Southern Europe (83%; 82-83%). The lowest survival was in Eastern Europe (74%; 74-75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients' age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe. Discussion SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices.
Published: 2015
Full Text: View/download PDF

14. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study

Author: Silvia Francisci, Pamela Minicozzi, Daniela Pierannunzio, Eva Ardanaz, Andrea Eberle, Tom K. Grimsrud, Arnold Knijn, Ugo Pastorino, Diego Salmerón, Annalisa Trama, Milena Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, M. Aarts, R. Damhuis, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Lung, Relative survival, business.industry, Large cell, Cancer, respiratory system, medicine.disease, Europe, Lung cancer, Morphology, Pleural cancer, Population-based cancer registries, Survival trends, Surgery, respiratory tract diseases, medicine.anatomical_structure, Internal medicine, Epidemiology of cancer, medicine, Carcinoma, Mesothelioma, business
Abstract: Background Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. Methods Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000–2007 by country/region, age and gender, and over time trends in 1999–2007 were estimated. Results Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5 years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. Conclusions Despite the generalised although slight increase, survival of lung and pleural cancer patients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
Published: 2015

15. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study

Author: Paolo Baili, Francesca Di Salvo, Rafael Marcos-Gragera, Sabine Siesling, Sandra Mallone, Mariano Santaquilani, Andrea Micheli, Roberto Lillini, Silvia Francisci, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Baili P., Salvo F.D., Marcos-Gragera R., Siesling S., Mallone S., Santaquilani M., Micheli A., Lillini R., Francisci S., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Pierannunzio D., Roazzi P., Rossi S., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Vilardell L., Sanchez M.J., Navarro C., Moreno-Iribas C., Ardanaz E., Galceran J., Lambe M., Khan S., Mousavi M., Bouchardy C., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Lemmens V., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., Baili, P, Di Salvo, F, Marcos Gragera, R, Siesling, S, Mallone, S, Santaquilani, M, Micheli, A, Lillini, R, Francisci, S, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
Subjects: Cancer Research, Population, Population-based cancer registrie, All cancer, Gross domestic product, Case-mix by cancer site, Case mix index, Health care, Medicine, education, METIS-311842, education.field_of_study, Relative survival, business.industry, Cancer, Cancer survival, Population-based cancer registries, medicine.disease, Eastern european, Oncology, EUROCARE, business, IR-97293, Demography
Abstract: Background: Overall survival after cancer is frequently used when assessing a health care service’s performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case- mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based cancer registries, using complete and period approach. Results: Denmark, United Kingdom (UK) and Eastern European countries had lower survival than neighbouring countries. Five-year ACRS has been increasing throughout Europe, and substantial increases, between 1999–2001 and 2005–2007, have been achieved in countries where survival was lower in the past. Five-year ACRS for men and women are positively correlated with macro-economic variables like the Gross Domestic Product (GDP) and Total National Expenditure on Health (TNEH) (R2 about 70%). Countries with recent larger increases in GDP and TNEH had greater increases in cancer survival. Conclusions: ACRS serves to compare all cancer survival in Europe taking account of the geographical variability in case-mixes. The EUROCARE-5 data on ACRS confirm previous EUROCARE findings. Survival appears to correlate with macro-economic determinants, particularly with investments in the health care system.
Published: 2015

16. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5

Author: Rafael Marcos-Gragera, Sandra Mallone, Lambertus A. Kiemeney, Loreto Vilardell, Núria Malats, Yves Allory, Milena Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A. M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, K. Aben, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Marcos-Gragera R., Mallone S., Kiemeney L.A., Vilardell L., Malats N., Allory Y., Sant M., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Serraino D., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
Subjects: Cancer Research, medicine.medical_specialty, Urinary system, Population, Population-based cancer registrie, Internal medicine, Medicine, education, Gynecology, education.field_of_study, Urinary bladder, Relative survival, business.industry, Urinary bladder tumours, Cancer survival, EUROCARE, Kidney cancer, Population-based cancer registries, Cancer, medicine.disease, Population based study, medicine.anatomical_structure, Oncology, business
Abstract: Background This work presents relative survival estimates regarding urinary tract tumours among adult patients (age ⩾ 15 years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000–2007, and on survival time trends from 1999–2001 to 2005–2007. Methods Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000–2007; the period approach was used to estimate survival over time. Results The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000–2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only. Conclusions Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
Published: 2015

17. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study

Author: Gemma Gatta, Laura Botta, María José Sánchez, Lesley Ann Anderson, Daniela Pierannunzio, Lisa Licitra, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, B. van Dijk, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: Larynx, Cancer Research, medicine.medical_specialty, Relative survival, business.industry, Advanced stage, Cancer, Disease, medicine.disease, Surgery, Population based study, medicine.anatomical_structure, Oncology, Europe, Head and neck cancers, Hypopharynx, Nasopharynx, Oral cavity, Oropharynx, Population-based study, Survival, Tongue, Internal medicine, Medicine, Stage (cooking), business, Head and neck
Abstract: BACKGROUND: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. METHODS: We analysed about 250, 000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub- site. RESULTS: Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five- year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five- year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). CONCLUSIONS: This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.
Published: 2015

18. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999- 2007: Results of EUROCARE-5

Author: Côme Lepage, Riccardo Capocaccia, Monika Hackl, Valerie Lemmens, Esther Molina, Daniela Pierannunzio, Milena Sant, Annalisa Trama, Jean Faivre, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, L. van der Geest, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., Sant M., Trama A., Faivre J., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Ma gi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapo tre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jo nasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sutera Sardo A., Mancuso P., Ferretti S., Crocetti E., Caldarella A., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Serraino D., Dal Maso L., De Angelis R., Caldora M., Carrani E., Francisci S., Mallone S., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Staiti R., Vitale F., Ravazzolo B., Michiara M., Tumino R., Giorgi Rossi P., Di Felice E., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., C. Fanetti A., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Bianconi F., Tagliabue G., Contiero P., Dei Tos A.P., Guzzinati S., Pildava S., Smailyte G., Calleja N., Agius D., Johannesen T.B., Rachtan J., Go zdz S., Me zyk R., Baszczyk J., Bebenek M., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Ramirez C., Errezola M., Bidaurrazaga J., Torrella-Ramos A., Diaz Garcia J.M., Jimenez-Chillaron R., Marcos-Gragera R., Izquierdo Font A., Sanchez M.J., Chang D.Y.L., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., van der Geest L., Otter R., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Donnelly C., Brewster D.H., Huws D.W., and White C.
Subjects: Cancer Research, medicine.medical_specialty, Survival, Biliary tract cancer, Cancer registry, Europe, Pancreatic cancer, Primary liver cancer, Time trends in survival, Oncology, Population, Socio-culturale, Gastroenterology, Internal medicine, medicine, education, Survival analysis, education.field_of_study, Relative survival, business.industry, Gallbladder, Cancer, medicine.disease, medicine.anatomical_structure, Liver cancer, business
Abstract: Background The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. Methods This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers (“biliary tract cancers”), and pancreatic cancer diagnosed in 2000–2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999–2007 were also analysed using the period approach. Results The prognosis of the studied cancers was poor. Age-standardised 5-year RS was 12% for liver cancer, 17% for biliary tract cancers and 7% for pancreatic cancer. There were some between-country differences in survival. In general, RS was low in Eastern Europe and high in Central and Southern Europe. For all sites, 5-year RS was similar in men and women and decreased with advancing age. No substantial changes in survival were reported for pancreatic cancer over the period 1999–2007. On average, there was a crude increase in 5-year RS of 3 percentage points between the periods 1999–2001 and 2005–2007 for liver cancer and biliary tract cancers. Conclusions The major changes in imaging techniques over the study period for the diagnosis of the three studied cancers did not result in an improvement in the prognosis of these cancers. In the near future, new innovative treatments might be the best way to improve the prognosis in these cancers.
Published: 2015

19. Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study

Author: Annalisa Trama, Roberto Foschi, Nerea Larrañaga, Milena Sant, Rafael Fuentes-Raspall, Diego Serraino, Andrea Tavilla, Liesbet Van Eycken, Nicola Nicolai, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M. F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M. J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S. M. Ess, H. Frick, M. Lorez, S.M. Ess, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Trama A., Foschi R., Larranaga N., Sant M., Fuentes-Raspall R., Serraino D., Tavilla A., Eycken L.V., Nicolai N., Hackl M., Zielonke N., Oberaigner W., Eycken E.V., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dusek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Belot A., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sardo A.S., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Salvo F.D., Margutti C., Meneghini E., Minicozzi P., Zucchetto A., Angelis R.D., Caldora M., Capocaccia R., Carrani E., Francisci S., Mallone S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Pannozzo F., Busco S., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Rossi P.G., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Tos A.P.D., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Gozdz R., Me zyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-Da-silva A., Nicula F., Coza D., Diba C.S., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Torrella-Ramos A., Garcia J.M.D., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Aben K., Coleman M., Allemani C., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., and White C.
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Survival, Relative survival, business.industry, Cancer registrie, Incidence (epidemiology), Prostate, Cancer, Penile cancer, medicine.disease, Prostate cancer, medicine.anatomical_structure, Internal medicine, Cancer registries, Penile cancers, Survival trends, Testicular, Survival trend, medicine, business, Penis, Testicular cancer
Abstract: Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000–2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999–2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. Conclusions Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients’ survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.
Published: 2015
Full Text: View/download PDF

20. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods

Author: Silvia Rossi, Paolo Baili, Riccardo Capocaccia, Massimiliano Caldora, Eugenio Carrani, Pamela Minicozzi, Daniela Pierannunzio, Mariano Santaquilani, Annalisa Trama, Claudia Allemani, Aurelien Belot, Carlotta Buzzoni, Matthias Lorez, Roberta De Angelis, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, V. Ho, S. Siesling, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, R. Otter, Rossi S., Baili P., Capocaccia R., Caldora M., Carrani E., Minicozzi P., Pierannunzio D., Santaquilani M., Trama A., Allemani C., Belot A., Buzzoni C., Lorez M., De Angelis R., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Zvolsky M., Dus?ek L., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Troussard X., Bouvier V., Launoy G., Guizard A.V., Faivre J., Bouvier A.M., Arveux P., Maynadie M., Woronoff A.S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Bossard N., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Meyer M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Kieschke J., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Giacomin A., Sutera Sardo A., Mazzei A., Ferretti S., Crocetti E., Manneschi G., Gatta G., Sant M., Amash H., Amati C., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Serraino D., Zucchetto A., Francisci S., Mallone S., Roazzi P., Tavilla A., Pannozzo F., Natali M., Bonelli L., Vercelli M., Gennaro V., Ricci P., Autelitano M., Randi G., Ponz De Leon M., Marchesi C., Cirilli C., Fusco M., Vitale M.F., Usala M., Traina A., Zarcone M., Vitale F., Cusimano R., Michiara M., Tumino R., Giorgi Rossi P., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Dei Tos A.P., Tognazzo S., Pildava S., Smailyte G., Calleja N., Micallef R., Johannesen T.B., Rachtan J., Gozdz S., Me zyk R., Baszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-da-Silva A., Nicula F., Coza D., Safaei Diba C., Primic-Zakelj M., Almar E., Mateos A., Errezola M., Larranaga N., Torrella-Ramos A., Diaz Garcia J.M., Marcos-Navarro A.I., Marcos-Gragera R., Vilardell L., Sanchez M.J., Molina E., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Ho V., Siesling S., Coleman M., Rachet B., Verne J., Easey N., Lawrence G., Moran T., Rashbass J., Roche M., Wilkinson J., Gavin A., Fitzpatrick D., Brewster D.H., Huws D.W., White C., and Otter R.
Subjects: Cancer Research, Survival, Population, Socio-culturale, Population-based registries, Population-based registrie, Quality checks, Cancer, EUROCARE, Europe, Oncology, Medicine, education, education.field_of_study, Relative survival, business.industry, Population size, Comparability, Percentage point, medicine.disease, Quality check, Data quality, Cohort, business, Demography
Abstract: Background Since 25 years the EUROCARE study monitors the survival of cancer patients in Europe through centralised collection, quality check and statistical analysis of population-based cancer registries (CRs) data. The European population covered by the study increased remarkably in the latest round. The study design and statistical methods were also changed to improve timeliness and comparability of survival estimates. To interpret the EUROCARE-5 results on adult cancer patients better here we assess the impact of these changes on data quality and on survival comparisons. Methods In EUROCARE-5 the survival differences by area were studied applying the complete cohort approach to data on nearly nine million cancer patients diagnosed in 2000–2007 and followed up to 2008. Survival time trends were analysed applying the period approach to data on about 10 million cancer cases diagnosed from 1995 to 2007 and followed up to 2008. Differently from EUROCARE-4, multiple primary cancers were included and relative survival was estimated with the Ederer II method. Results EUROCARE-5 covered a population of 232 million resident persons, corresponding to 50% of the 29 participating countries. The population coverage increased particularly in Eastern Europe. Cases identified from death certificate only (DCO) were on average 2.9%, range 0–12%. Microscopically confirmed cases amounted to over 85% in most CRs. Compared to previous methods, including multiple cancers and using the Ederer II estimator reduced survival estimates by 0.4 and 0.3 absolute percentage points, on average. Conclusions The increased population size and registration coverage of the EUROCARE-5 study ensures more robust and comparable estimates across European countries. This enlargement did not impact on data quality, which was generally satisfactory. Estimates may be slightly inflated in countries with high or null DCO proportions, especially for poor prognosis cancers. The updated methods improved the comparability of survival estimates between recently and long-term established registries and reduced biases due to informative censoring.
Published: 2015

21. Non-small-cell lung cancer in a French department, (1982–1997): management and outcome

Author: Marie-Paule Lebitasy, A Purohit, G. Hedelin, M. Velten, J. Foeglé, and Elisabeth Quoix
Subjects: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Palliative care, medicine.medical_treatment, Population, Antineoplastic Agents, chemotherapy, survival, surgery, Carcinoma, Non-Small-Cell Lung, Internal medicine, Clinical Studies, medicine, Humans, Lung cancer, education, Survival rate, radiotherapy, Aged, Retrospective Studies, Chemotherapy, education.field_of_study, business.industry, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Surgery, Survival Rate, Radiation therapy, Treatment Outcome, non-small-cell lung cancer, Chemotherapy, Adjuvant, Adenocarcinoma, Female, Radiotherapy, Adjuvant, France, business, management
Abstract: Addition of chemotherapy to the treatment of non-small-cell lung cancer (NSCLC) resulted in a modest but clear improvement in the survival of selected patients. To ascertain if this translates to improved survival in the whole population of patients, we conducted a retrospective population-based study of a sample of 1738 patients diagnosed with primary NSCLC in a French department between 1982 and 1997. The proportion of women, metastatic cases and adenocarcinoma changed significantly over time, as did their management: use of chemotherapy alone increased from 9.7 to 28.1% (P
Published: 2005
Full Text: View/download PDF

22. Impact of a Specific One-on-One Announcement Procedure Provided by a Radiation Therapist Before Radiation Therapy: Results of a Prospective Randomized Controlled Trial

Author: P. Truntzer, N. Bauer, E. Rieger, M. Velten, Sébastien Guihard, P. Salze, Jean-Baptiste Clavier, C. Vigneron, Marius Pop, Delphine Antoni, and Georges Noël
Subjects: Cancer Research, medicine.medical_specialty, Radiation, business.industry, Radiation Therapist, medicine.medical_treatment, law.invention, Radiation therapy, Oncology, Randomized controlled trial, law, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, business
Published: 2016
Full Text: View/download PDF

23. Multifokales ERG mit 30-Hz-Flimmerstimulation bei Glaukompatienten und Normalprobanden

Author: Matthias Korth, Isabel M. Velten, and Folkert K. Horn
Subjects: Gynecology, Ophthalmology, medicine.medical_specialty, business.industry, Reference values, Healthy subjects, Medicine, business
Abstract: Hintergrund. Ziel der vorliegenden Studie war es, die Wertigkeit der 30-Hz-Flimmerstimulation im multifokalen ERG fur die Glaukomdiagnostik zu untersuchen. Methoden. Multifokale ERGs wurden mit einem 30-Hz-Flimmerstimulus von 61 Hexagonen nach maximaler Pupillendilatation von einem zentralen 60°-Bereich der Retina abgeleitet (mittlere Leuchtdichte 50 cd/m2, 99% Kontrast). Jeweils ein Auge von 30 Patienten mit primaren und sekundaren Offenwinkel- und Normaldruckglaukomen mit reproduzierbaren glaukomatosen Gesichtsfeldausfallen und glaukomatoser Optikusatrophie sowie von 21 Normalprobanden wurde in die Studie eingeschlossen. Ausgewertet wurden die 1. harmonische Oberwelle, die Fundamentale sowie der Quotient aus beiden. Fur den intraokularen Vergleich von Arealen mit und ohne perimetrische Defekte sowie fur den Vergleich zwischen Glaukomen und Normalen wurden die Antworten von jeweils 7 benachbarten Hexagonen gemittelt. Ergebnisse. Bei den Glaukompatienten zeigte sich im intraokularen Vergleich in einem Areal innerhalb eines Gesichtsfeldausfalls ein signifikant niedrigerer Quotient aus 1. harmonischer Oberwelle und Fundamentaler als auserhalb des Ausfalls (p
Published: 2002
Full Text: View/download PDF

24. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

Author: Delphine Berchery, Barbara Pistilli, Véronique Diéras, C. Courtinard, Paul-Henri Cottu, Laurence Vanlemmens, Lilian Laborde, Suzette Delaloge, D. Parent, M. Robain, Marc Debled, Thomas Bachelot, M. Leheurteur, E. Jacquet, M. Velten, William Jacot, J-M Ferrero, Bruno Coudert, G. Anne-Valérie, and Audrey Lardy-Cleaud
Subjects: Oncology, medicine.medical_specialty, Chemotherapy, biology, business.industry, medicine.medical_treatment, First line, Endocrine therapy, Hematology, medicine.disease, Metastatic breast cancer, Internal medicine, medicine, biology.protein, Observational study, Aromatase, business
Published: 2017
Full Text: View/download PDF

25. Retrospective analysis of bevacizumab use in combination with irinotecan for recurrent glioblastoma: a single-institution experience

Author: C. Besson, W. Waissi, Nelly Etienne-Selloum, R. Schott, M. Velten, L. Nguyen Them, and D. Prebay
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, Recurrent glioblastoma, Irinotecan, Internal medicine, medicine, Retrospective analysis, Single institution, business, medicine.drug
Published: 2017
Full Text: View/download PDF

26. The a-wave of the dark adapted electroretinogram in glaucomas: are photoreceptors affected?

Author: Folkert K. Horn, Matthias Korth, and Isabel M. Velten
Subjects: Adult, medicine.medical_specialty, genetic structures, Open angle glaucoma, Glaucoma, Luminance, Cellular and Molecular Neuroscience, chemistry.chemical_compound, Ophthalmology, Electroretinography, medicine, Humans, Scotopic vision, Aged, medicine.diagnostic_test, Adaptation, Ocular, business.industry, Retinal, Middle Aged, Original articles - Clinical science, medicine.disease, eye diseases, Sensory Systems, Low Tension Glaucoma, chemistry, Case-Control Studies, Visual Field Tests, sense organs, business, Erg, Photoreceptor Cells, Vertebrate
Abstract: AIMS—To evaluate whether the a-wave of the dark adapted flash electroretinogram (ERG) is affected by glaucomatous damage. METHODS—ERGs were recorded in 20 patients (age 33-65 years) with advanced glaucomas (primary and secondary open angle and low tension glaucomas) and 20 normals using a ganzfeld stimulus. After 30 minutes of dark adaptation and pupil dilatation to at least 7.5 mm in diameter, luminance response functions were obtained presenting white flashes of increasing scotopic luminance (the highest flash intensity being 9.4 cd/s/m2, the lowest being 5.75 log units below it) with an interflash interval of 5 seconds. For each scotopic luminance, the responses of four flashes were averaged. The a-wave's amplitude was measured at 10, 11, and 12 ms. Within the glaucoma group, correlations between the interocular differences of the a-wave's amplitude and the mean deviation of a static perimetry (Octopus 500 perimeter, program G1) were computed for all flash intensities. Between normals and glaucomas, the a-wave's amplitude was compared for all flash intensities (paired t test). RESULTS—Within the glaucoma group, the interocular differences of the a-wave's amplitudes correlated significantly with the differences of the MD for flash intensities of 9.4, 5.3, 1.7, and 0.5 cd/s/m2. The a-wave's amplitude was significantly lower in the glaucoma compared with the normal group (p
Published: 2001
Full Text: View/download PDF

27. The b-wave of the dark adapted flash electroretinogram in patients with advanced asymmetrical glaucoma and normal subjects

Author: Kai Velten, Matthias Korth, Isabel M. Velten, and Folkert K. Horn
Subjects: Adult, Intraocular pressure, medicine.medical_specialty, genetic structures, Open angle glaucoma, Glaucoma, Adaptation (eye), Models, Biological, Statistics, Nonparametric, Cellular and Molecular Neuroscience, Ophthalmology, Electroretinography, Reaction Time, Humans, Medicine, Scotopic vision, Aged, medicine.diagnostic_test, Adaptation, Ocular, business.industry, Middle Aged, Original articles - Clinical science, medicine.disease, eye diseases, Sensory Systems, Visual field, Low Tension Glaucoma, Case-Control Studies, Visual Field Tests, sense organs, business
Abstract: AIMS—To evaluate whether the b-wave of the dark adapted flash electroretinogram (ERG) is affected by glaucomatous damage. METHODS—ERGs were recorded in 35 patients aged 33-65 years with advanced asymmetrical glaucomas (interocular difference of perimetric defects (mean deviation) >2 dB between the two fellow eyes of the glaucoma patients, primary and secondary open angle and low tension glaucomas) and 17 normal subjects matched for age and sex using white flashes of a xenon discharge tube in a Ganzfeld stimulator. After 30 minutes of dark adaptation luminance response functions were obtained using flashes of increasing scotopic luminance (highest 9.4 cd/s/m2, lowest 5.5 log units below it). The parameters Vmax, n, and K of the Naka-Rushton equation were computed from the measurement values based on the usual fitting procedure. These parameters, together with b-wave amplitudes and implicit times for all flash intensities, were compared interocularly and between the normal subjects and those with glaucoma. Correlations were computed between interocular differences of the mean deviation and interocular differences of Vmax, n, K, b-wave amplitudes, and implicit times between the two fellow eyes of the patients with asymmetrical glaucomatous damage. RESULTS—Implicit times were significantly longer (p
Published: 2001
Full Text: View/download PDF

28. Zentrale Hornhautdicke bei Normalen, Patienten mit okulärer Hypertension, Normaldruck- und Offenwinkelglaukomen - eine klinische Studie12

Author: Anselm Jünemann, Matthias Korth, Folkert K. Horn, Antonio Bergua, and Isabel M. Velten
Subjects: Applanation tonometry, medicine.medical_specialty, genetic structures, Open angle glaucoma, medicine.diagnostic_test, business.industry, Eye disease, Ocular hypertension, medicine.disease, eye diseases, Goldmann applanation tonometry, Low Tension Glaucoma, Ophthalmology, medicine.anatomical_structure, Cornea, medicine, sense organs, Corneal pachymetry, business
Abstract: BACKGROUND The relation between Goldmann applanation tonometry and central corneal thickness (CCT) was investigated in several studies during the last thirty years. It was the aim of the present study to evaluate CCT in normals, patients with ocular hypertension, low-tension, and open-angle glaucomas. PATIENTS AND METHODS CCT was measured in 135 normal eyes, 137 with ocular hypertension, 65 with low-tension, and 94 with primary and secondary open-angle glaucomas using the AL-11000-pachymeter (Tomey). The results were compared using the unpaired t-test. RESULTS CCT was significantly higher in the patients with ocular hypertension (586 +/- 43 microns) than in the normal group (566 +/- 37 microns, p < 0.0001), in low-tension glaucomas (555 +/- 46 microns, p < 0.0001), and in open-angle glaucomas (558 +/- 31 microns, p < 0.0001). The latter three groups did not differ significantly. There was no significant correlation between CCT and age, the actually measured IOP, the highest IOP in the patient's history, or the spherical equivalent. CONCLUSIONS Only patients with ocular hypertension showed a significant difference in CCT compared with normals. Pachymetry thus should be conducted in those patients to avoid overestimation of the IOP by applanation tonometry. In most of the patients with low-tension and open-angle glaucomas however, CCT regarded without other parameters (e.g. corneal or scleral rigidity) plays a minor role in detection of elevated IOP according to the results of this study.
Published: 2000
Full Text: View/download PDF

29. Synopsis verschiedener sinnesphysiologischer Untersuchungen in der Glaukom-Frühdiagnose - Zeitliche und örtlich-zeitliche Kontrastempfindlichkeit, Helligkeits- und Farbkontrast-Muster-ERG, Blau-auf-gelb-VEP12

Author: Martin Wisse, Peter Martus, Antonio Bergua, Folkert K. Horn, Claus Cursiefen, Anselm G. Jünemann, Matthias Korth, Wido M. Budde, and Isabel M. Velten
Subjects: medicine.medical_specialty, Pathology, Retina, Intraocular pressure, genetic structures, medicine.diagnostic_test, business.industry, media_common.quotation_subject, Glaucoma, Ocular hypertension, medicine.disease, eye diseases, Visual field, Ophthalmology, medicine.anatomical_structure, medicine, Contrast (vision), sense organs, Evoked potential, business, Electroretinography, media_common
Abstract: BACKGROUND Of the three glaucoma-defining criteria intraocular pressure, optic-nerve damage, and visual field damage, the latter is a late symptom. Therefore, in order to improve an early sensory diagnosis, new tests are necessary. It is the aim of the present paper to test new sensory methods, to rank them in an order of sensitivity, and to base them on possible pathophysiological mechanisms. PATIENTS AND METHODS The tests were carried out in subjects of the Erlangen Glaucoma registry: Normals, patients with ocular hypertension, and patients with open-angle glaucoma without or with field defects. The tests are designed to preferentially probe the function of different groups of ganglion cells. Psychophysical methods: Temporal contrast sensitivity in a ganzfeld as "Erlangen flicker test" and spatio-temporal contrast sensitivity to test Magno-cell function. Electrophysiological methods: Pattern-reversal electroretinogram with a luminance-contrast pattern to test Magno-cell function, color-contrast pattern electroretinogram for Parvo-cell function, and blue-on-yellow visual evoked potential to test the "blue-sensitive" pathway. RESULTS The most sensitive test is the temp.CS, it is significantly reduced in OHT (p < 0.01). The spatio-temp.CS is reduced in perimetric stages (p < 0.01). The BY-VEP is altered in the preperimetric stage (p < 0.01), the PR-ERG in perimetric stages (p < 0.01). The CC-ERG is reduced in even later stages. These results are in agreement with the hypothesis that tests selective for non-redundant neurons are of early diagnostic value. Multivariate analyses increase the early diagnostic value when different functions are tested in combination. CONCLUSIONS When a particular test is taylored to the the special needs of certain groups of ganglion cells sensory defects can be observed before the occurrence of optic-nerve damage (OHT). The most sensitive psychophysical test is the "Erlangen flicker test" which is a screening test selective for M cells. The most sensitive electrophysiological test is the BY-VEP testing the blue-sensitive ganglion cells.
Published: 2000
Full Text: View/download PDF

30. Individualisation du ganglion axillaire sentinelle par colorant lymphotrope dans les cancers du sein. Étude de faisabilité à propos de 128 cas

Author: Jean-François Rodier, C. Barlier, Hervé Mignotte, J. C. Janser, T. Routiot, Jean-Pierre Ghnassia, M Velten, C Chassagne, Isabelle Treilleux, and Alain Brémond
Subjects: Gynecology, Stage classification, medicine.medical_specialty, business.industry, Medicine, Surgery, business, Predictive factor
Abstract: Resume But de l'etude Ce travail portant sur le ganglion axillaire sentinelle dans le cancer du sein a pour objet d'etudier la faisabilite technique de son individualisation et la predictivite sur le statut lymphatique de l'aisselle. Patients et methodes Entre janvier 1996 et juin 1997, 128 malades atteints de cancers invasifs du sein ont beneficie, aux centres regionaux de lutte contre le cancer de Strasbourg et de Lyon, d'une individualisation du ganglion axillaire sentinelle par injection de colorant lymphotrope (bleu Patent) suivie d'une lymphadenectomie axillaire (etages I a II de Berg). Resultats Le taux d'opacification du ganglion axillaire sentinelle a ete de 76,5 % et sa predictivite du statut axillaire de 94,9 %. Le taux de faux negatifs de la procedure a ete de 5,1 %. L'envahissement histologique du ganglion axillaire sentinelle a ete de 43,9 % et son envahissement etait isole dans 30,2 %. La sensibilite de la technique a ete de 94 % (IC95 % = [88 %–98 %]) et sa specificite de 100 %. Conclusion Bien que devant etre encore consideree comme une voie de recherche en cours d'evaluation dans le cadre d'essais prospectifs controles, cette etude atteste de la faisabilite et de la reproductibilite d'une technique qui devrait, dans un proche avenir, ouvrir la voie d'une chirurgie axillaire mini-invasive de stadification dans les cancers du sein.
Published: 1998
Full Text: View/download PDF

31. Évaluation du risque d'envahissement ganglionnaire axillaire dans les cancers du sein inférieurs à 3 centimètres. Analyse d'un modèle prédictif à partir de 893 cas

Author: B. Cutuli, D. Jaeck, R. Renaud, P Quetin, Jean-François Rodier, G Duperoux, M Velten, and J. C. Janser
Subjects: Gynecology, medicine.medical_specialty, business.industry, Medicine, Surgery, business
Abstract: Resume But de l'etude II s'agit d'une analyse combinee de facteurs cliniques et histologiques (determines a partir d'une microbiopsie prealable) ayant pour objet d'evaluer le risque d'envahissement ganglionnaire axillaire (pN + ) dans les cancers du sein inferieurs a 3 cm. Materiel et methodes Chez 893 patientes atteintes d'un cancer invasif du sein ToT 1 T 2 ≤ 3 cm cinq parametres ont ete analyses: la taille clinique ( T ), la taille histologique (pT), le sous-type histologique (carcinome canalaire infiltrant, divise selon les trois grades histopronostiques SBR, carcinome lobulaire infiltrant et autres), l'âge ( 60 ans) et la taille du sein, determinee objectivement sur un critere dosimetrique recemment publie ( Eur J Cancer 1997; 33: 2432–4). Resultats Le taux global de pN + etait de 25,3 %, avec respectivement: pN1: 10 %, pN2-3: 8,4 % et pN > 3: 6,9 %. Pour les t 0 , T 1 et T 2 ≤ 3 les taux de pN + etaient respectivement de 13,8 %, 19,8 % et 36,2 %. Selon le pT on notait respectivement 11,1 %, 17,7 %, 23,5 %, 30,1 % et 36 % de pN + pour les lesions correspondantes: 09,9 mm, 10–14,9 mm, 15–19,9 mm, 20–24,9 mm et 259,9 mm. Pour les carcinomes canalaires infiltrants SBR 1, 2 et 3 les taux de pN + etaient de 18,3 %, 27,2 % et 37,8 %; pour les carcinomes lobulaires infiltrants et les autres soustypes, de 22,7 % et 10 %. Pour les trois categories d'âge sus-citees, les taux de pN + etaient respectivement 30,3 %, 25,8 % et 22,4 %. Selon la taille du sein, il y avait 30,1 % et 24,4 % de pN + pour les seins de petit volume par rapport a ceux de moyen ou gros volume. Apres analyse multivariee, trois facteurs restaient significativement predictifs pour le risque de pN + : la taille clinique de la tumeur ( p p = 0,0005), la taille du sein ( p = 0,004). En combinant simultanement ces trois facteurs, le risque de pN + variait de 5 a 50 %. De plus, il etait egalement possible de predire le nombre de ganglions envahis. Conclusions Ce modele simple peut permettre au clinicien d'identifier un groupe de patientes dont le risque d'envahissement ganglionnaire axillaire est ≤ 30 % et qui pourrait donc beneficier d'une chirurgie axillaire limitee avec analyse du ganglion sentinelle.
Published: 1998
Full Text: View/download PDF

32. Cancer prevalence estimates in Europe at the beginning of 2000

Author: G. Gatta, S. Mallone, J.M. van der Zwan, A. Trama, S. Siesling, R. Capocaccia, M. Hackl, E. Van Eycken, K. Henau, G. Hedelin, M. Velten, G. Launoy, A.V. Guizard, A.M. Bouvier, M. Maynadié, A.-S. Woronoff, A. Buemi, M. Colonna, O. Ganry, P. Grosclaude, B. Holleczek, H. Ziegler, L. Tryggvadottir, F. Bellù, S. Ferretti, D. Serraino, L. Dal Maso, E. Bidoli, S. Birri, A. Zucchetto, L. Zainer, M. Vercelli, M.A. Orengo, C. Casella, A. Quaglia, M. Federico, I. Rashid, C. Cirilli, M. Fusco, A. Traina, M. Michiara, V. De Lisi, F. Bozzani, A. Giacomin, R. Tumino, M.G. La Rosa, E. Spata, A. Signora, L. Mangone, F. Falcini, S. Giorgetti, A. Ravaioli, G. Senatore, A. Iannelli, M. Budroni, S. Piffer, S. Franchini, E. Crocetti, A. Caldarella, T. Intrieri, F. La Rosa, F. Stracci, T. Cassetti, P. Contiero, G. Tagliabue, P. Zambon, S. Guzzinati, F. Berrino, P. Baili, F. Bella, R. Ciampichini, C. Margutti, A. Micheli, P. Minicozzi, M. Sant, M. Caldora, E. Carrani, R. De Angelis, S. Francisci, E. Grande, R. Inghelmann, H. Lenz, L. Martina, P. Roazzi, M. Santaquilani, A. Simonetti, A. Tavilla, A. Verdecchia, F. Langmark, J. Rachtan, R. Mężyk, S. Góżdź, U. Siudowska, M. Zwierko, M. Bielska-Lasota, Ch. Safaei Diba, M. Primic-Zakelj, A. Mateos, I. Izarzugaza, A. Torrella Ramos, O. Zurriaga, R. Marcos-Gragera, M.L. Vilardell, A. Izquierdo, E. Ardanaz, C. Moreno-Iribas, J. Galceran, Å. Klint, M. Talbäck, G. Jundt, M. Usel, H. Frick, S.M. Ess, A. Bordoni, I. Konzelmann, S. Dehler, O. Visser, R. Otter, J.W.W. Coebergh, D.C. Greenberg, J. Wilkinson, M. Roche, J. Verne, D. Meechan, J. Poole, G. Lawrence, A. Gavin, D.H. Brewster, R.J. Black, J.A. Steward, University of Zurich, Gatta, G, Faculty of Behavioural, Management and Social Sciences, and Usel, Massimo
Subjects: Male, aging, cancer, cancer registry, Europe, prevalence, 2720 Hematology, Neoplasms, Health care, Prevalence, Medicine, Registries, Young adult, Child, Health statistics, METIS-296763, Aged, 80 and over, Registries/statistics & numerical data, Hematology, Middle Aged, Europe, Oncology, Child, Preschool, Vital Status, Female, 2730 Oncology, Adult, Population ageing, Adolescent, prevalence, 610 Medicine & health, Europe/epidemiology, NO, Young Adult, 10049 Institute of Pathology and Molecular Pathology, Humans, cancer, cancer registry, Cancer prevalence, ddc:613, Aged, business.industry, aging, Infant, Newborn, IR-86376, Neoplasms/diagnosis/epidemiology, Cancer, Infant, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), medicine.disease, cancer prevalence, Cancer registry, business, Demography
Abstract: Background Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 major cancers in Europe at the beginning of the year 2003. Patients and methods We estimated complete prevalence by the completeness index method. We used information on cancer patients diagnosed in 1978–2002 with vital status information available up to 31 December 2003, from 76 European cancer registries. Results About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on 1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with a previous diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase the number of prevalent cases to nearly 13 millions in 2010. Conclusions Several factors (early detection, population aging and better treatment) contribute to increase cancer prevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resource allocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should be included within the EU official health statistics
Published: 2013

33. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas

Author: S, Caillard, F X, Lamy, C, Quelen, J, Dantal, Y, Lebranchu, P, Lang, M, Velten, B, Moulin, and M, Buchler
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, Adolescent, Lymphoma, medicine.medical_treatment, Lymphoproliferative disorders, Pancreas transplantation, Gastroenterology, Young Adult, Postoperative Complications, Risk Factors, hemic and lymphatic diseases, Internal medicine, medicine, Immunology and Allergy, Humans, Pharmacology (medical), Cumulative incidence, Registries, Kidney transplantation, Transplantation, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Immunosuppression, Middle Aged, medicine.disease, Kidney Transplantation, Lymphoproliferative Disorders, surgical procedures, operative, Immunology, Female, France, Pancreas Transplantation, business
Abstract: A registry of posttransplant lymphoproliferative disorders (PTLD) was set up for the entire population of adult kidney transplant recipients in France. Cases of PTLD were prospectively enrolled between January 1, 1998, and December 31, 2007. Ten-year cumulative incidence was analyzed in patients transplanted after January 1, 1989. PTLD risk factors were analyzed in patients transplanted after January 1, 1998 by Cox analysis. Cumulative incidence was 1% after 5 years, 2.1% after 10 years. Multivariate analysis showed that PTLD was significantly associated with: older age of the recipient 47-60 years and >60 years (vs. 33-46 years, adjusted hazard ratio (AHR) = 1.87, CI = 1.22-2.86 and AHR = 2.80, CI = 1.73-4.55, respectively, p < 0.0001), simultaneous kidney-pancreas transplantation (AHR = 2.52, CI = 1.27-5.01 p = 0.008), year of transplant 1998-1999 and 2000-2001 (vs. 2006-2007, AHR = 3.36, CI = 1.64-6.87 and AHR = 3.08, CI = 1.55-6.15, respectively, p = 0.003), EBV mismatch (HR = 5.31, CI = 3.36-8.39, p < 0.001), 5 or 6 HLA mismatches (vs. 0-4, AHR = 1.54, CI = 1.12-2.12, p = 0.008), and induction therapy (AHR = 1.42, CI = 1-2.02, p = 0.05). Analyses of subgroups of PTLD provided new information about PTLD risk factors for early, late, EBV positive and negative, polymorphic, monomorphic, graft and cerebral lymphomas. This nationwide study highlights the increased risk of PTLD as long as 10 years after transplantation and the role of cofactors in modifying PTLD risk, particularly in specific PTLD subgroups.
Published: 2012

34. Abduktionsdefizit als Erstsymptom eines Bronchialkarzinoms1

Author: Bernd Tomandl, Isabel M. Velten, and Gabriele Ch. Gusek-Schneider
Subjects: Diplopia, medicine.medical_specialty, genetic structures, medicine.diagnostic_test, business.industry, Eye disease, Lateral rectus muscle, Magnetic resonance imaging, medicine.disease, Extraocular muscles, eye diseases, Surgery, Ophthalmology, medicine.anatomical_structure, Ptosis, Cavernous sinus, Carcinoma, medicine, sense organs, Radiology, medicine.symptom, business
Abstract: Background: Patients: In about 30% of patients with orbital metastases, these metastases are detected before the primary tumour is known. Less than 5% of orbital metastases are located in extraocular muscles. We report on a patient with diplopia caused by diminished abduction of the left eye as first symptom of a bronchogenic carcinoma. Patient: A 86-year-old patient presented with a newly developed diplopia. On examination, the left eye showed a diminished abduction, ptosis and miosis. Pharmacological testing revealed peripheral Horner's syndrome. On cranial magnet resonance tomography, the lateral rectus muscle belly was enlarged. A chest X-ray showed a large tumour (6 cm in diameter) of the left upper lobe with multiple metastases to the lungs. Further examinations revealed a large cell bronchogenic carcinoma with metastases to the lungs, adrenal glands, and the lateral rectus muscle. Conclusions: Diplopia caused by metastases to extraocular muscles is rare as first sign of a bronchogenic carcinoma. The combination of peripheral Horner's syndrome with diminished abduction of the homolateral eye primarily suggests a lesion of the cavernous sinus. The bronchogenic carcinoma could not be causative for Horner's syndrome in the patient presented here, however an undetected tumor-infiltration of the postganglionic region cannot be excluded. This case demonstrates that in all patients with newly developed diplopia and Horner's syndrome, even in absence of orbital signs, apart from a ophthalmological examination detailed radiographic or magnetic resonance tomographic imaging is necessary of both skull base and orbita.
Published: 2000
Full Text: View/download PDF

35. Gibt es eine korneale okuläre 'Pseudo-Hypertension'?

Author: Anselm Jünemann, Wido M. Budde, and Isabel M. Velten
Subjects: medicine.medical_specialty, genetic structures, medicine.diagnostic_test, business.industry, Eye disease, Applanation tonometer, Ocular hypertension, medicine.disease, eye diseases, Goldmann applanation tonometry, Ophthalmology, medicine.anatomical_structure, Cornea, Pseudohypertension, medicine, In patient, sense organs, Corneal pachymetry, business
Abstract: BACKGROUND The relation between Goldmann applanation tonometry and central corneal thickness (CCT) was evaluated in several studies during the last thirty years. Patients with ocular hypertension were found to have a significantly higher CCT compared with normals and glaucomas. PATIENTS To report on two sisters with elevated CCT and ocular hypertension diagnosed by raised intraocular-pressure (IOP) readings on Goldmann applanation tonometry. RESULTS In both patients, there were no signs for early functional or morphological glaucomatous changes. Maximum IOP was 30 mm Hg and 26 mm Hg. The corneal pachymetry revealed an increased CCT in both patients (700 and 680 microns, respectively), while corneal morphology was normal. CONCLUSIONS Ocular hypertension can be misdiagnosed by too high applanation tonometer readings in patients with markedly elevated CCT. Before the onset of treatment thus, corneal pachymetry should be performed in patients with ocular hypertension to exclude ocular "pseudohypertension" and to avoid unneccessary treatment.
Published: 1999
Full Text: View/download PDF

36. Central corneal thickness correlated with glaucoma damage and rate of progression

Author: Jost B. Jonas, Isabel M. Velten, Wido M. Budde, Peter Martus, Anselm G M Juenemann, and Andrea Stroux
Subjects: Adult, medicine.medical_specialty, genetic structures, Open angle glaucoma, Adolescent, Optic Disk, Glaucoma, Ocular hypertension, Cornea, Tonometry, Ocular, Ophthalmology, Optic Nerve Diseases, Medicine, Humans, Body Weights and Measures, Prospective Studies, Corneal pachymetry, Child, Aged, medicine.diagnostic_test, business.industry, Middle Aged, medicine.disease, eye diseases, Visual field, medicine.anatomical_structure, Chronic Disease, Optic nerve, Disease Progression, Ocular Hypertension, sense organs, Visual Fields, business, Glaucoma, Open-Angle, Optic disc, Follow-Up Studies
Abstract: PURPOSE. To evaluate whether the amount of glaucomatous optic nerve damage at presentation of the patient and the rate of progression of glaucoma during follow-up are related to central corneal thickness. METHODS. The prospective observational clinical study included 861 eyes of 454 white subjects (239 normal eyes of 121 subjects, 250 ocular hypertensive eyes of 118 patients, 372 eyes of 215 patients with chronic open-angle glaucoma). For 567 eyes (304 patients) with ocular hypertension or chronic open-angle glaucoma, follow-up examinations were performed, with a mean follow-up time of 62.7 33.2 months (median, 60.8; range, 6.2–124.9). All patients underwent qualitative and morphometric evaluation of color stereo optic disc photographs and white-on-white visual field examination. Central corneal thickness was measured by corneal pachymetry. RESULTS. Central corneal thickness correlated significantly (P 0.001) and positively with the area of the neuroretinal rim and negatively with the loss of visual field. Development or progression of glaucomatous visual field defects detected in 119 (21.0%) eyes was statistically independent of central corneal thickness, in univariate (P 0.99) and multivariate Cox regression analyses (P 0.19). CONCLUSIONS. At the time of patient referral, the amount of glaucomatous optic nerve damage correlated significantly with a thin central cornea. Progression of glaucomatous optic nerve neuropathy was independent of central corneal thickness, suggesting that central corneal thickness may not play a major role in the pathogenesis of progressive glaucomatous optic nerve damage. (Invest Ophthalmol Vis Sci. 2005;46:1269 –1274)
Published: 2005

37. The full-field flicker test in glaucomas: influence of intraocular pressure and pattern of visual field losses

Author: Anselm Jünemann, Isabel M. Velten, Matthias Korth, and Folkert K. Horn
Subjects: Male, medicine.medical_specialty, Intraocular pressure, genetic structures, media_common.quotation_subject, Eye disease, Glaucoma, Contrast Sensitivity, Flicker Fusion, Cellular and Molecular Neuroscience, Ophthalmology, medicine, Contrast (vision), Humans, Scotoma, Intraocular Pressure, media_common, business.industry, Flicker, fungi, Reproducibility of Results, Middle Aged, medicine.disease, eye diseases, Sensory Systems, Visual field, ROC Curve, Fixation (visual), Chronic Disease, Visual Field Tests, Female, Visual Fields, business, Glaucoma, Open-Angle, Photopic vision
Abstract: The purpose of this study was to evaluate how temporal contrast sensitivity (TCS) determined with full-field flicker stimuli is influenced by intraocular pressure and whether TCS is reduced in glaucoma patients with diffuse perimetric losses as well as in patients with localized visual field deficits.TCS was determined with sinusoidally flickering light (37.1 Hz) in a full-field bowl. Perimetric mean defect (MD) and cumulative defect curves (Octopus G1) were used to distinguish between patients with localized and diffuse field deficits. Normal subjects (296), low-tension glaucoma patients (98) and open-angle glaucoma patients with previously elevated intraocular pressure (541) were classified into five subgroups taking into account the depth of their visual field losses.No significant correlation between full-field flicker sensitivity and prevailing intraocular pressure was found in normals (Y=1.36+0.006 X) or in patients (Y=0.95-0.0002 X). Analyses of validity at a predefined specificity of 90% reveal a reduction of TCS in patients with early (MD5 dB) diffuse perimetric losses (sensitivity 69%) as well as in those showing localized visual field defects (sensitivity 65%). Sensitivity was 87% in patients with diffuse perimetric defects (MD 5-10 dB), 93% in a group of patients with both types of losses, and 100% in advanced glaucomas (MD20 dB). The lack of TCS is similar in open-angle glaucomas and in field-loss-matched normal-tension glaucoma patients.Significantly reduced TCS in patients with early diffuse perimetric losses as well as in those showing localized visual field defects indicates that localized damages can be associated with general deterioration of the ability to perceive flickering stimuli. Thus, this flicker test can be performed in a full-field bowl with no need for fixation. Considering its other clinical qualities (photopic conditions, low influence of prevailing intraocular pressure and media opacity) the test may be a useful, convenient supplementary procedure in glaucoma screening.
Published: 1999

38. Long term results after breast conservative treatment. Analysis of 652 cases

Author: G. Duperoux, M. Velten, B. Cutuh, R. Renaud, D. Jaeck, A. Karst, and Jean-François Rodier
Subjects: Conservative treatment, medicine.medical_specialty, business.industry, medicine, Surgery, General Medicine, Long term results, business
Published: 1997
Full Text: View/download PDF

39. Unilateral arcus lipoides corneae with contralateral Sturge-Weber syndrome

Author: Gottfried O. H. Naumann, Wido M. Budde, and Isabel M. Velten
Subjects: medicine.medical_specialty, Intraocular pressure, genetic structures, business.industry, medicine.medical_treatment, Carotid arteries, Sturge–Weber syndrome, Glaucoma, Diathermy, medicine.disease, eye diseases, Sensory Systems, Surgery, Cellular and Molecular Neuroscience, Ophthalmology, Ciliary body, medicine.anatomical_structure, Medicine, Trabeculectomy, sense organs, Letters to the Editor, business, Arcus lipoides corneae
Abstract: Editor,—Arcus lipoides corneae usually occurs bilaterally and symmetrically.1 Pronounced unilateral arcus lipoides corneae occurs in atrophic eyes, less marked with relative ocular hypotension2-4 or contralateral carotid artery stenosis.5-7 We report on a patient with unilateral arcus lipoides in the normal eye sparing the other one with Sturge–Weber syndrome. ### CASE REPORT A 33 year old patient showed a left sided secondary juvenile open angle glaucoma due to Sturge–Weber syndrome. The glaucoma diagnosed at the age of 10 months with a maximum intraocular pressure (IOP) of 40 mm Hg had been treated twice by diathermy of the ciliary body, and once by trabeculectomy during the first 6 years of life. Since then, the …
Published: 2000
Full Text: View/download PDF

40. Conservative treatment of infraclinical breast cancer: Analyses of 184 cases

Author: J.C. Janser, G.M. Jung, D. Jaeck, Bruno Cutuli, M. Velten, and R. Renaud
Subjects: Conservative treatment, Oncology, Cancer Research, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, medicine, business, medicine.disease
Published: 1993
Full Text: View/download PDF

41. Display Techniques for Advanced Crew Stations (DTACS). Phase 1. Display Techniques Study

Author: H E Dillard, E C Adam, J Guenther, and R M Velten
Subjects: Engineering, Aeronautics, business.industry, Crew, ComputerApplications_COMPUTERSINOTHERSYSTEMS, Plan (drawing), Avionics, business, Phase (combat)
Abstract: The DTACS Final Report describes the study which explored advanced display techniques and their effect on future fighter/attack aircraft crew stations. The emphasis was placed on new and developing technology with applications to integrated avionics systems. Future mission requirements were reviewed, display requirements were established, display technologies were reviewed, an initial configuration of an advanced display was made and a plan for further development was also prepared.
Published: 1984
Full Text: View/download PDF

42. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: results from EUROCARE-5

Author: L.A. Anderson, A. Tavilla, H. Brenner, S. Luttmann, C. Navarro, A.T. Gavin, B. Holleczek, B.T. Johnston, M.B. Cook, F. Bannon, M. Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dusek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, A. Eberle, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter
Subjects: medicine.medical_specialty, Cancer Research, Survival, Europe, Oesophageal, Small intestine, Stomach, Gastroenterology, Article, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, In patient, Stomach cancer, Relative survival, business.industry, Cancer, Patient survival, medicine.disease, medicine.anatomical_structure, Oncology, business, Small intestine cancer, Demography
Abstract: Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995–1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999–2001 to 2005–2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised ‘complete analysis’ RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999–2001, 2002–2004 and 2005–2007 were investigated using the ‘period’ RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005–2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005–2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005–2007, with Central, Southern and Eastern Europe showing the greatest increases (⩾9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.
Full Text: View/download PDF

43. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diff use large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)

Author: Bernard Rachet, Pamela Minicozzi, Laura Botta, Milena Sant, Christian Herrmann, Pascale Grosclaude, Giovanna Tagliabue, ROCH GIORGI, Mariano Santaquilani, Meneghini Elisabetta, Aurélien Belot, Roberta De Angelis, Stefano Ferretti, Silvia Francisci, Paolo Contiero, Alexander Katalinic, Neville Calleja, Franco Berrino, Laurent Remontet, Paolo Baili, David Brewster, BOSSARD Nadine, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Registre des hémopathies malignes de Côte d'Or, London School of Hygiene and Tropical Medicine (LSHTM), IRCCS Istituto Nazionale dei Tumori [Milano], Istituto Superiore di Sanità (ISS), Epidemiologie-Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux Ségalen [Bordeaux 2], Institut Bergonié [Bordeaux], UNICANCER, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Bourgogne (UB), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), M Mägi, T Aareleid, M Velten, J Faivre, M Maynadié, A S Woronoff, B Tretarre, N Bossard, A Belot, M Colonna, B Lapôtre-Ledoux, P Grosclaude, H Brenner, A Nennecke, B Holleczek, A Katalinic, J G Jónasson, L Tryggvadóttir, G Mazzoleni, A Bulatko, C Buzzoni, A Giacomin, S Ferretti, G Gatta, M Sant, H Amash, C Amati, P Baili, F Berrino, S Bonfarnuzzo, L Botta, F Di Salvo, R Foschi, C Margutti, E Meneghini, P Minicozzi, A Trama, R De Angelis, M Caldora, R Capocaccia, E Carrani, S Francisci, S Mallone, D Pierannunzio, P Roazzi, S Rossi, M Santaquilani, A Tavilla, F Pannozzo, M Natali, L Bonelli, M Vercelli, C Marchesi, C Cirilli, M Fusco, M F Vitale, M Michiara, R Tumino, P Giorgi Rossi, M Vicentini, F Falcini, O Sechi, R Cesaraccio, S Piffer, G Tagliabue, P Contiero, G Smailyte, N Calleja, R Micallef, T B Johannesen, M Bielska-Lasota, C Safaei Diba, M Primic-Zakelj, M Errezola, N Larrañaga, R Marcos-Gragera, L Vilardell, M J Sanchez, E Molina, C Navarro, M D Chirlaque, C Moreno-Iribas, E Ardanaz, J Galceran, M Carulla, M Mousavi, S M Ess, H Frick, M Lorez, S M Ess, C Herrmann, I Konzelmann, O Visser, V Lemmens, R Otter, M Coleman, C Allemani, B Rachet, J Verne, N Easey, G Lawrence, T Moran, J Rashbass, M Roche, J Wilkinson, D H Brewster, D W Huws, C White, Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Istituto Superiore di Sanita [Rome], Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), and Malbec, Odile
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Pediatrics, Adolescent, [SDV]Life Sciences [q-bio], Follicular lymphoma, Autopsy, NO, minimum clinical recommendations, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, medicine, follow up, Humans, 030212 general & internal medicine, Young adult, cancer survival, Lymphoma, Follicular, Non-Hodgkin lymphoma, Aged, Hematology, Wales, minimum clinical recommendations, Non-Hodgkin lymphoma, relative survival, cancer survival, follow up, business.industry, Cancer, relative survival, Middle Aged, medicine.disease, 3. Good health, Lymphoma, [SDV] Life Sciences [q-bio], Europe, Scotland, 030220 oncology & carcinogenesis, Female, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, International Classification of Diseases for Oncology
Abstract: Summary Background Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collaborative European population-based cancer registries (EUROCARE). Methods We considered follicular lymphoma and diffuse large B-cell lymphoma cases in patients aged older than 15 years diagnosed between Jan 1, 1996, and Dec 31, 2004, and recorded in 43 cancer registries in five areas: Scotland and Wales, and northern, central, eastern, and southern Europe. We excluded cases incidentally diagnosed at autopsy or known from death certificates only. The vital status could be updated on Dec 31, 2008, in all registries but the French ones (Dec 31, 2007). We obtained changes in net survival with the Pohar-Perme estimator and excess mortality rate with a flexible parametric model according to age and year of diagnosis. Findings We identified 13 988 follicular lymphoma and 25 320 diffuse large B-cell lymphoma cases. We noted improvements in 5-year net survival for all ages between the 1999–2001 and 2002–04 periods for both cancers (except for follicular lymphoma in Scotland and Wales and diffuse large B-cell lymphoma in eastern Europe). For follicular lymphoma, 5-year net survival in northern Europe was 64% (95% CI 58–71) in 1999–2001 versus 75% (69–80) for 2002–04, for Scotland and Wales, it was 71% (66–76) versus 68% (64–72), for central Europe, it was 64% (61–67) versus 72% (70–75), for southern Europe, it was 67% (63–70) versus 73% (70–76), and for eastern Europe, it was 50% (43–57) versus 61% (54–69). For diffuse large B-cell lymphoma, 5-year net survival in northern Europe was 41% (35–49) versus 58% (54–62), in Scotland and Wales, it was 44% (41–48) versus 52% (49–54), in central Europe, it was 46% (44–47) versus 50% (48–51), in southern Europe, it was 44% (42–47) versus 50% (48–52), and in eastern Europe, it was 47% (41–54) versus 46% (43–50). We noted the largest area disparity during the 2002–04 period between eastern and northern Europe. We noted a significant effect of the year of diagnosis on the excess mortality rate for all ages in all areas, except for diffuse large B-cell lymphoma in eastern Europe. The excess mortality rate was not constant during the follow-up period: we noted a high rate early for both lymphomas, except for follicular lymphoma in northern Europe. Interpretation Although survival for follicular lymphoma and diffuse large B-cell lymphoma is improving, the results from this study should foster the search for more and better means of improvement of access to adequate care than that at present, as there remains variation in survival between European regions. Study of the dynamics of the excess mortality rate seems to be a useful clinical indicator to help the practitioner's choice of optimum management of patients. Funding Compagnia di San Paolo, Fondazione Cariplo Italy, Italian Ministry of Health, European Commission, Registre des Hemopathies Malignes de Cote d'Or, and French Agence Nationale de la Recherche.
Published: 2015
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

43 results on '"M. Velten"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources